Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cara Therapeutics, Inc.    CARA

CARA THERAPEUTICS, INC.

(CARA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Cara: 3Q Earnings Snapshot

11/09/2020 | 04:18pm EST

STAMFORD, Conn. (AP) _ Cara Therapeutics Inc. (CARA) on Monday reported a loss of $16.5 million in its third quarter.

On a per-share basis, the Stamford, Connecticut-based company said it had a loss of 35 cents.

The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 68 cents per share.

The biotechnology company posted revenue of $9.3 million in the period, which also beat Street forecasts. Four analysts surveyed by Zacks expected $5 million.

Cara shares have fallen almost 10% since the beginning of the year. In the final minutes of trading on Monday, shares hit $14.54, a decline of 30% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CARA at https://www.zacks.com/ap/CARA

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about CARA THERAPEUTICS, INC.
01/12CARA THERAPEUTICS : Initiates Phase 2 Trial of Oral KORSUVA for the Treatment of..
AQ
01/11CARA THERAPEUTICS : Begins Phase II Study of Difelikefalin for Treatment of Prur..
MT
01/11Cara Initiates Phase 2 Trial of Oral KORSUVA™ for the Treatment of Prur..
GL
01/06CARA THERAPEUTICS : to Present at the 39th Annual J.P. Morgan Healthcare Confere..
AQ
2020CARA THERAPEUTICS : Submits New Drug Application to U.S. Food and Drug Administr..
AQ
2020CARA THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exh..
AQ
2020CARA THERAPEUTICS : Submits New Drug Application for Korsuva Injection
MT
2020Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administ..
GL
2020SWK : ' Subsidiary, Enteris BioPharma, Receives $2.5Million Milestone Payment fr..
MT
2020CARA THERAPEUTICS : SWK Holdings' Subsidiary, Enteris BioPharma, Receives Second..
PR
More news
Financials (USD)
Sales 2020 65,7 M - -
Net income 2020 -53,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -12,7x
Yield 2020 -
Capitalization 925 M 925 M -
Capi. / Sales 2020 14,1x
Capi. / Sales 2021 32,8x
Nbr of Employees 76
Free-Float 83,9%
Chart CARA THERAPEUTICS, INC.
Duration : Period :
Cara Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 33,13 $
Last Close Price 18,56 $
Spread / Highest target 116%
Spread / Average Target 78,5%
Spread / Lowest Target -3,02%
EPS Revisions
Managers and Directors
NameTitle
Derek T. Chalmers President, Chief Executive Officer & Director
Thomas Reilly Chief Financial & Accounting Officer
Frèdèrique Menzaghi Chief Scientific Officer, Senior VP-R&D
Joana Goncalves Chief Medical Officer
Martin A. Vogelbaum Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CARA THERAPEUTICS, INC.22.67%925
MODERNA, INC.24.10%51 304
LONZA GROUP AG3.27%49 041
CELLTRION, INC.-12.53%40 715
IQVIA HOLDINGS INC.4.81%36 004
SEAGEN INC.6.06%33 601